TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20565212

Group type: EXPERIMENTAL
Intervention: Articulation of several different distractor items with increased distractor interval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated articulations of the same word between list items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type of distractors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total duration of distractors
Number of subjects: 0
Study: 18294739

Group type: EXPERIMENTAL
Intervention: Active group supplemented daily with 6 mg lutein combined with vitamins and minerals
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 46
Study: 15792395

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 500 microg via Diskus, twice daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 500 microg via Diskus, single dose
Number of subjects: 14
Study: 12527527

Group type: EXPERIMENTAL
Intervention: Ropivacaine (20 ml)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Bupivacaine (20 ml)
Number of subjects: 65
Study: 10389800

Group type: EXPERIMENTAL
Intervention: Flexible laryngeal mask airway (FLMA) with Boyle Davis (B-D) gag
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flexible laryngeal mask airway (FLMA) without Boyle Davis (B-D) gag
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flexible laryngeal mask airway (FLMA)
Number of subjects: 20
Study: 8542688

Group type: EXPERIMENTAL
Intervention: External spinal skeletal fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 0
Study: 1871399

Group type: EXPERIMENTAL
Intervention: Pregnancy survey by midwives at home for the prevention of prematurity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Program of prevention of ill-treatment of very young children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Program of prevention of sexually transmitted diseases and their complications on sterility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Campaign to support women deciding to breast-feed
Number of subjects: 0
Study: 6875167

Group type: EXPERIMENTAL
Intervention: Rotating gratings treatment (n = 20)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (n = 18) - viewed a blank rotating disc for 15 minutes once a week for ten weeks
Number of subjects: 38
Study: 30639752

Group type: EXPERIMENTAL
Intervention: 5 face‐to‐face visits with a psychologist and exercise specialist over 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 face‐to‐face visits with a psychologist and exercise specialist over 3 months plus technology‐based behavior change support package for an additional 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 29795283

Group type: EXPERIMENTAL
Intervention: Hydrogen-water bathing
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 27763623

Group type: EXPERIMENTAL
Intervention: Clinical COPD Questionnaire (CCQ) in 2005
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Clinical COPD Questionnaire (CCQ) in 2012
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Linear regression analysis including baseline CCQ, sex, age, educational level, BMI, smoking status, heart disease, diabetes, depression, number of exacerbations, dyspnoea (mMRC)
Number of subjects: 970
Study: 25241544

Group type: EXPERIMENTAL
Intervention: OUYA FIBER posts
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tenax Fiber White posts
Number of subjects: 120
Study: 22176795

Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA) delivered via contraceptive vaginal ring, 600-800 mcg
Number of subjects: 39
Study: 20307949

Group type: EXPERIMENTAL
Intervention: HPLC/MS/MS method for simultaneous determination of furosemide, spironolactone, and canrenone
Number of subjects: 0
Study: 18039282

Group type: EXPERIMENTAL
Intervention: Statistical methods including Oldham's method and multilevel modelling
Number of subjects: 0

Group type: COMPARATOR
Intervention: ANCOVA
Number of subjects: 0
Study: 16330998

Group type: EXPERIMENTAL
Intervention: Trident insert encased in a titanium sleeve
Number of subjects: 316

Group type: COMPARATOR
Intervention: Alumina bearing couple
Number of subjects: 316
Study: 12025827

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Combination therapy (Nefazodone + CBASP)
Number of subjects: 681

Group type: COMPARATOR
Intervention: CBASP
Number of subjects: 681
Study: 10584048

Group type: EXPERIMENTAL
Intervention: Omnivorous diet (mixed-diet group)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Lactoovovegetarian diet (LOV-diet group)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 19
Study: 8723300

Group type: EXPERIMENTAL
Intervention: Obsessive auditory stimulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neutral auditory stimulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: OCD patients
Number of subjects: 10
Study: 1854361

Group type: EXPERIMENTAL
Intervention: Fluvastatin (XU 62-320)
Number of subjects: 0
Study: 6717701

Group type: EXPERIMENTAL
Intervention: Low dialysate magnesium concentration in 12 patients
Number of subjects: 22
Study: 31014176

Group type: EXPERIMENTAL
Intervention: Check Yourself (electronic screening and feedback tool)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Visit alone (control group)
Number of subjects: 84
Study: 30281882

Group type: EXPERIMENTAL
Intervention: Enhanced Adherence Counselling (EAC)
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Tracing (TRIC)
Number of subjects: 513
Study: 26872302

Group type: EXPERIMENTAL
Intervention: 16-week moderate-intensity exercise intervention (150 minutes of moderate-intensity aerobic exercise per week)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 16-week moderate-intensity exercise intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 101
Study: 23864069

Group type: EXPERIMENTAL
Intervention: Information with reminders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Information with reminders and implementation intentions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information alone
Number of subjects: 0
Study: 22459628

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Recombinant FSH (rFSH)
Number of subjects: 1506
Study: 20090550

Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus-eluting coronary stent system
Number of subjects: 600

Group type: COMPARATOR
Intervention: Taxus Liberté Paclitaxel Eluting Coronary Stent System
Number of subjects: 600
Study: 19102185

Group type: EXPERIMENTAL
Intervention: Hamstring tendon
Number of subjects: 32

Group type: COMPARATOR
Intervention: Allograft
Number of subjects: 32
Study: 17768809

Group type: EXPERIMENTAL
Intervention: 5 mg/kg caffeine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 9 mg/kg caffeine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11828556

Group type: EXPERIMENTAL
Intervention: Limited palmar incision CTR
Number of subjects: 72

Group type: COMPARATOR
Intervention: Traditional open technique CTR
Number of subjects: 72
Study: 10455342

Group type: EXPERIMENTAL
Intervention: G-CSF treatment starting at day 1
Number of subjects: 38

Group type: COMPARATOR
Intervention: G-CSF treatment starting at day 6
Number of subjects: 38
Study: 8569137

Group type: EXPERIMENTAL
Intervention: Continuous infusion of fentanyl and midazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single dose application of fentanyl and midazolam
Number of subjects: 0
Study: 2239569

Group type: EXPERIMENTAL
Intervention: Ofloxacin 300 mg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Ofloxacin 600 mg
Number of subjects: 84
Study: 725560

Group type: EXPERIMENTAL
Intervention: Björk-Shiley valves
Number of subjects: 300

Group type: COMPARATOR
Intervention: Lillehei-Kaster valves
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both valves
Number of subjects: 300
Study: 31039812

Group type: EXPERIMENTAL
Intervention: Metallic stent group (MSG)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Ordinary polymer stent group (OPSG)
Number of subjects: 76
Study: 28479220

Group type: EXPERIMENTAL
Intervention: Emergency Department Electronic Medication Complete Communication (EMC2) Opioid Strategy with text messaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emergency Department Electronic Medication Complete Communication (EMC2) Opioid Strategy without text messaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 26168409

Group type: EXPERIMENTAL
Intervention: Intensive arm (six face-to-face sessions followed by nine telephone sessions)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Intensive arm
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control arm (leaflet advising on healthy lifestyle)
Number of subjects: 170
Study: 23513199

Group type: EXPERIMENTAL
Intervention: 10 to 16 mm-long hydroxyapatite-coated implants after lateral sinus lifting with 50% organic bovine (Bio-Oss) and 50% autogenous bone (20 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 8 mm implants after crestal sinus lifting with autogenous bone (20 patients)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Long implants
Number of subjects: 40

Group type: COMPARATOR
Intervention: Short implants
Number of subjects: 40
Study: 21659406

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation training for cricothyroidotomy
Number of subjects: 38
Study: 19375849

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 17019629

Group type: EXPERIMENTAL
Intervention: Alone/camera present
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Other present/camera present
Number of subjects: 43

Group type: COMPARATOR
Intervention: Clinic observation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Home observation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Weekly assessments
Number of subjects: 43
Study: 15043515

Group type: EXPERIMENTAL
Intervention: Infliximab pre-treated patients
Number of subjects: 313

Group type: COMPARATOR
Intervention: Control group (infliximab naive)
Number of subjects: 313
Study: 11813899

Group type: COMPARATOR
Intervention: Ventilation tube (VT) only
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ventilation tube (VT) + Meniett
Number of subjects: 20
Study: 9260418

Group type: EXPERIMENTAL
Intervention: Compomer Dyract
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hybrid composite resin Prisma TPH
Number of subjects: 60
Study: 7917814

Group type: EXPERIMENTAL
Intervention: High-volume lignocaine gel preparations (> 20 ml) with no antiseptic
Number of subjects: 106

Group type: COMPARATOR
Intervention: Other preparations of lignocaine gel (exact details not specified)
Number of subjects: 106
Study: 3048077

Group type: EXPERIMENTAL
Intervention: High carbohydrate, low fiber (HC, LF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High carbohydrate, high fiber (HC, HF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low carbohydrate, low fiber (LC, LF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low carbohydrate, high fiber (LC, HF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of soy polysaccharide (10 g)
Number of subjects: 0
Study: 31176669

Group type: EXPERIMENTAL
Intervention: Blood protein biosignature consisting of 6 proteins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 30901502

Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA) + Membrane Filtration (MF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immunoadsorption (IA) alone
Number of subjects: 0
Study: 29141784

Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 412

Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Low sodium-DASH diet
Number of subjects: 412
Study: 27342765

Group type: EXPERIMENTAL
Intervention: Choline intake of 930 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Choline intake of 480 mg/d
Number of subjects: 0
Study: 22326568

Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenge (DBPCFC) with low-lactose cow's milk
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Open oral challenge test with 200 mL of low-lactose cow's milk
Number of subjects: 58
Study: 21212155

Group type: EXPERIMENTAL
Intervention: Sorafenib (800 mg/day) + Gemcitabine (1200 mg/m² on days 1 and 8, every 21 days for a maximum of six cycles)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sorafenib (800 mg/day) + Erlotinib (150 mg/day)
Number of subjects: 60
Study: 19448383

Group type: EXPERIMENTAL
Intervention: Supervised physical exercise (E)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unsupervised regular walking (W)
Number of subjects: 50
Study: 16932240

Group type: EXPERIMENTAL
Intervention: Testosterone patch (300 microg/day)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 549
Study: 15271748

Group type: EXPERIMENTAL
Intervention: Vellore regimen (combined glucose insulin and variable rate infusion)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (existing techniques)
Number of subjects: 204
Study: 11357960

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 9374685

Group type: EXPERIMENTAL
Intervention: GLP-1-(7-36) amide (0.4, 0.8, or 1.2 pmol.kg-1.min-1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: GLP-1-(7-37) (1.2 pmol.kg-1.min-1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: GLP-1-(7-36) amide and GLP-1-(7-37)
Number of subjects: 9
Study: 8181617

Group type: EXPERIMENTAL
Intervention: Oxpentifylline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3282032

Group type: EXPERIMENTAL
Intervention: Long-term maintenance chemotherapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: No postremission therapy (control)
Number of subjects: 51
Study: 30146138

Group type: EXPERIMENTAL
Intervention: Breathing meditation (condition 1)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Emotion-focused meditation (condition 2)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control condition (condition 3)
Number of subjects: 65
Study: 26971257

Group type: EXPERIMENTAL
Intervention: 10 simulated procedures
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 30 simulated procedures
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no simulator training)
Number of subjects: 66
Study: 23989970

Group type: EXPERIMENTAL
Intervention: Call-up maneuver of manual lymphatic drainage
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Reabsorption maneuver of manual lymphatic drainage
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 41
Study: 22447850

Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison of both medications
Number of subjects: 28
Study: 20539246

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (100-200 mg/d)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Escitalopram (10-20 mg/d)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 100
Study: 19128626

Group type: EXPERIMENTAL
Intervention: Illustrated handout
Number of subjects: 51

Group type: COMPARATOR
Intervention: Pure text handout
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Illustrated handout (1 year follow-up)
Number of subjects: 51
Study: 15926058

Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy (MED)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Microdiscectomy (MD)
Number of subjects: 33

Group type: COMPARATOR
Intervention: One-level unilateral laminotomy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All surgical procedures
Number of subjects: 33
Study: 12784519

Group type: EXPERIMENTAL
Intervention: Marburger Rechtschreibtraining (spelling training program)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no tutoring)
Number of subjects: 37
Study: 10933349

Group type: EXPERIMENTAL
Intervention: Provisional stenting (group 1)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Systematic stenting (group 2)
Number of subjects: 251
Study: 8610868

Group type: EXPERIMENTAL
Intervention: Hyaluronidase (100 IU = 2 mL) with bupivacaine 0.5% (5.5 mL) and lidocaine 2% (5.5 mL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Plain bupivacaine 0.5% (5.5 mL) and lidocaine 2% (5.5 mL) without hyaluronidase
Number of subjects: 21
Study: 8438979

Group type: EXPERIMENTAL
Intervention: Health education classes combined with a payroll‐based incentive system
Number of subjects: 10000
Study: 3101549

Group type: EXPERIMENTAL
Intervention: Morphine sulfate 0.2 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Morphine sulfate 0.4 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ketamine 1.1 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ketamine 3.0 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ketamine 3.0 mg/kg with morphine
Number of subjects: 6
Study: 29785522

Group type: EXPERIMENTAL
Intervention: Non-invasive vagus nerve stimulation (nVNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC) treatment
Number of subjects: 0
Study: 27916213

Group type: EXPERIMENTAL
Intervention: Esomeprazole (40mg once daily)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Esomeprazole (40mg twice daily for nonresponders)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Esomeprazole (dose decreased by half for responders)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Esomeprazole (dose increased for nonresponders)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 24033480

Group type: EXPERIMENTAL
Intervention: 600 mg dose of aspirin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23979627

Group type: EXPERIMENTAL
Intervention: VF waveform analysis algorithm
Number of subjects: 987

Group type: COMPARATOR
Intervention: Standard shock-first protocol
Number of subjects: 987
Study: 20958958

Group type: EXPERIMENTAL
Intervention: Assertive community treatment for the elderly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study: 18953882

Group type: EXPERIMENTAL
Intervention: FTQ combined with cisplatin
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (tegafur + cisplatin)
Number of subjects: 119
Study: 16185206

Group type: EXPERIMENTAL
Intervention: Intelligence (IQ)
Number of subjects: 1799

Group type: COMPARATOR
Intervention: Socio-economic position (SEP)
Number of subjects: 1799
Study: 12939228

Group type: EXPERIMENTAL
Intervention: Black women with coronary artery disease
Number of subjects: 2699
Study: 10831008

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aqueous nasal spray (220 microg)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Loratadine (10 mg)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aqueous nasal spray
Number of subjects: 351

Group type: COMPARATOR
Intervention: Loratadine
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 351
Study: 9019583

Group type: EXPERIMENTAL
Intervention: Electrophysiological study
Number of subjects: 3
Study: 1732426

Group type: EXPERIMENTAL
Intervention: Carboplatin 560 mg/m2 at 4-week intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iproplatin 270 mg/m2 at 3-week intervals
Number of subjects: 0
Study: 3891946

Group type: EXPERIMENTAL
Intervention: Prophylactic phototherapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Routine phototherapy (after serum bilirubin concentration reached 5 mg/dl)
Number of subjects: 22
Study: 30412927

Group type: EXPERIMENTAL
Intervention: Geoff (painted anatomical horse)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Textbook (control)
Number of subjects: 45
Study: 29216395

Group type: EXPERIMENTAL
Intervention: DSM265 (400 mg oral dose) administered 3 days before CHMI
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DSM265 (400 mg oral dose) administered 7 days before CHMI
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 27086250

Group type: EXPERIMENTAL
Intervention: Association Splitting
Number of subjects: 84

Group type: COMPARATOR
Intervention: Exercise Therapy
Number of subjects: 84
Study: 24871652

Group type: EXPERIMENTAL
Intervention: True acupuncture (electroacupuncture at the Hegu [LI4] and Zusanli [ST36] acupoints, as well as acupuncture at the Ear Shenmen)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acupuncture (minimal acupuncture at the Hegu and Zusanli acupoints without electrical stimulation and superficial acupuncture at the Ear Shenmen)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 60
Study: 22342199

Group type: EXPERIMENTAL
Intervention: Arthroscopic treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open treatment
Number of subjects: 50
Study: 19591010

Group type: EXPERIMENTAL
Intervention: E(2) 1.0 mg
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: E(2) 0.5 mg
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 18417186

Group type: EXPERIMENTAL
Intervention: Amblyopic eyes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short duration plaid stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long duration plaid stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fellow-fixing eyes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control eyes
Number of subjects: 0
Study: 15790044

Group type: EXPERIMENTAL
Intervention: Albendazole (800 mg/d for 28 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (surgery only)
Number of subjects: 30